tetano
Editor, Senior Moderator
Antiviral Res
. 2023 Jul 20;105676.
doi: 10.1016/j.antiviral.2023.105676. Online ahead of print. Ceragenins exhibit antiviral activity against SARS-CoV-2 by increasing the expression and release of type I interferons upon activation of the host's immune response
Łukasz Suprewicz[SUP] 1 [/SUP], Artur Szczepański[SUP] 2 [/SUP], Marzena Lenart[SUP] 2 [/SUP], Ewelina Piktel[SUP] 3 [/SUP], Krzysztof Fiedoruk[SUP] 1 [/SUP], Emilia Barreto-Duran[SUP] 2 [/SUP], Anna Kula-Pacurar[SUP] 2 [/SUP], Paul B Savage[SUP] 4 [/SUP], Aleksandra Milewska[SUP] 2 [/SUP], Robert Bucki[SUP] 5 [/SUP], Krzysztof Pyrć[SUP] 6 [/SUP]
Affiliations
The COVID-19 pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) heavily burdened the entire world socially and economically. Despite a generation of vaccines and therapeutics to confront infection, it remains a threat. Most available antivirals target viral proteins and block their activity or function. While such an approach is considered effective and safe, finding treatments for specific viruses of concern leaves us unprepared for developed resistance and future viral pandemics of unknown origin. Here, we propose ceragenins (CSAs), synthetic amphipathic molecules designed to mimic the properties of cationic antimicrobial peptides (cAMPs), as potential broad-spectrum antivirals. We show that selected CSAs exhibit antiviral activity against SARS-CoV-2 and low-pathogenic human coronaviruses 229E, OC43, and NL63. The mechanism of action of CSAs against coronaviruses is mainly attributed to the stimulation of antiviral cytokines, such as type I interferons or IL-6. Our study provides insight into a novel immunomodulatory strategy that might play an essential role during the current pandemic and future outbreaks.
Keywords: Antivirals; Ceragenins; Human coronaviruses; SARS-CoV-2; Type I interferon.
. 2023 Jul 20;105676.
doi: 10.1016/j.antiviral.2023.105676. Online ahead of print. Ceragenins exhibit antiviral activity against SARS-CoV-2 by increasing the expression and release of type I interferons upon activation of the host's immune response
Łukasz Suprewicz[SUP] 1 [/SUP], Artur Szczepański[SUP] 2 [/SUP], Marzena Lenart[SUP] 2 [/SUP], Ewelina Piktel[SUP] 3 [/SUP], Krzysztof Fiedoruk[SUP] 1 [/SUP], Emilia Barreto-Duran[SUP] 2 [/SUP], Anna Kula-Pacurar[SUP] 2 [/SUP], Paul B Savage[SUP] 4 [/SUP], Aleksandra Milewska[SUP] 2 [/SUP], Robert Bucki[SUP] 5 [/SUP], Krzysztof Pyrć[SUP] 6 [/SUP]
Affiliations
- PMID: 37481038
- DOI: 10.1016/j.antiviral.2023.105676
The COVID-19 pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) heavily burdened the entire world socially and economically. Despite a generation of vaccines and therapeutics to confront infection, it remains a threat. Most available antivirals target viral proteins and block their activity or function. While such an approach is considered effective and safe, finding treatments for specific viruses of concern leaves us unprepared for developed resistance and future viral pandemics of unknown origin. Here, we propose ceragenins (CSAs), synthetic amphipathic molecules designed to mimic the properties of cationic antimicrobial peptides (cAMPs), as potential broad-spectrum antivirals. We show that selected CSAs exhibit antiviral activity against SARS-CoV-2 and low-pathogenic human coronaviruses 229E, OC43, and NL63. The mechanism of action of CSAs against coronaviruses is mainly attributed to the stimulation of antiviral cytokines, such as type I interferons or IL-6. Our study provides insight into a novel immunomodulatory strategy that might play an essential role during the current pandemic and future outbreaks.
Keywords: Antivirals; Ceragenins; Human coronaviruses; SARS-CoV-2; Type I interferon.